← Leaderboards
Eric J Sorscher
Emory University
$13,371,665
Attributed
$18,314,050
Total exposure
15
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,900,835 · 17
FDA$1,625,000 · 1
By mechanism
P30$14,517,461 · 8
R01$13,776,433 · 5
P50$5,846,919 · 2
M01$385,022 · 2
U19$0 · 1
Top collaborators
- John L. Hartman8 shared
- Brian R. Davis5 shared
- Eben L Rosenthal4 shared
Others in their field
Top investigators on “Cystic Fibrosis”
- John F Engelhardt · University Of Iowa$42,933,706
- Michael R Knowles · University Of North Carolina Chapel Hill$30,250,682
- David A Stoltz · University Of Iowa$25,455,359
- Joseph Zabner · University Of Iowa$25,382,103
- Paul B McCray · University Of Iowa$25,146,293
- Richard C Boucher · University Of North Carolina Chapel Hill$24,890,955
Research focus
Cystic FibrosisBaseInnovationHuman SubjectPathogenesisIn VivoTechnologyCystic Fibrosis Transmembrane Conductance RegulatorFutureAreaTranslational ResearchMediatingMolecularCellsLaboratoriesGenesMutationDefectRanpirnaseFoundationsResearch PersonnelIon TransportFundingPrograms
Grant awards (81)
Discovery of novel mechanisms that impact CFTR translation and contribute to cystic fibrosis pathogenesis$551,534
R01 · FY2025 · HL · contact PI
Discovery of novel mechanisms that impact CFTR translation and contribute to cystic fibrosis pathogenesis$540,504
R01 · FY2024 · HL · contact PI
Discovery of novel mechanisms that impact CFTR translation and contribute to cystic fibrosis pathogenesis$551,534
R01 · FY2023 · HL · contact PI
Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicine$736,241
R01 · FY2022 · HL · contact PI
Discovery of novel mechanisms that impact CFTR translation and contribute to cystic fibrosis pathogenesis$579,784
R01 · FY2022 · HL · contact PI
P & F Sorscher$85,728
P30 · FY2022 · DK · contact PI
Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicine$745,791
R01 · FY2021 · HL · contact PI
Ribosomal perturbation as a mechanism to prevent misfolding of CFTR$556,180
R01 · FY2021 · HL · contact PI
Phase I - II Study of Ad/PNP(IND14271,1/19/10)for HNSCC(OrphanDrugDes,14-4438,6/8/15)$500,000
R01 · FY2021 · FD · contact PI
Intratumoral generation of F-Ade to ablate low growth fraction HNSCC$442,836
R01 · FY2021 · DE · contact PI
Phase I - II Study of Ad/PNP(IND14271,1/19/10)for HNSCC(OrphanDrugDes,14-4438,6/8/15)$125,000
R01 · FY2021 · FD · contact PI
P & F Sorscher$85,703
P30 · FY2021 · DK · contact PI
Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicine$757,115
R01 · FY2020 · HL · contact PI
Ribosomal perturbation as a mechanism to prevent misfolding of CFTR$556,180
R01 · FY2020 · HL · contact PI
Phase I - II Study of Ad/PNP(IND14271,1/19/10)for HNSCC(OrphanDrugDes,14-4438,6/8/15)$500,000
R01 · FY2020 · FD · contact PI
Intratumoral generation of F-Ade to ablate low growth fraction HNSCC$442,836
R01 · FY2020 · DE · contact PI
P & F Sorscher$70,103
P30 · FY2020 · DK · contact PI
Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicine$758,201
R01 · FY2019 · HL · contact PI
Ribosomal perturbation as a mechanism to prevent misfolding of CFTR$556,180
R01 · FY2019 · HL · contact PI
Intratumoral generation of F-Ade to ablate low growth fraction HNSCC$448,832
R01 · FY2019 · DE · contact PI
Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicine$786,347
R01 · FY2018 · HL · contact PI
Ribosomal perturbation as a mechanism to prevent misfolding of CFTR$584,180
R01 · FY2018 · HL · contact PI
Phase I - II Study of Ad/PNP(IND14271,1/19/10)for HNSCC(OrphanDrugDes,14-4438,6/8/15)$500,000
R01 · FY2018 · FD · contact PI
Intratumoral generation of F-Ade to ablate low growth fraction HNSCC$453,330
R01 · FY2018 · DE · contact PI
Intratumoral generation of F-Ade to ablate low growth fraction HNSCC$463,582
R01 · FY2017 · DE · contact PI
Pilot and Feasibility Program$219,750
P30 · FY2016 · DK · contact PI
Administrative Component$116,289
P30 · FY2016 · DK · contact PI
Pilot and Feasibility Program$219,750
P30 · FY2015 · DK · contact PI
Administrative Component$116,289
P30 · FY2015 · DK · contact PI
UAB CF Research and Translation Core Center$1,087,084
P30 · FY2014 · DK · contact PI
Pilot and Feasibility Program$219,750
P30 · FY2014 · DK · contact PI
Administrative Component$116,289
P30 · FY2014 · DK · contact PI
UAB CF Research and Translation Core Center$1,025,120
P30 · FY2013 · DK · contact PI
Pilot and Feasibility Program$207,357
P30 · FY2013 · DK · contact PI
Administrative Component$103,897
P30 · FY2013 · DK · contact PI
UAB CF Research and Translation Core Center$1,099,084
P30 · FY2012 · DK · contact PI
Pilot and Feasibility Program$231,750
P30 · FY2012 · DK · contact PI
Administrative Component$116,289
P30 · FY2012 · DK · contact PI
UAB CF Research and Translation Core Center$861,058
P30 · FY2011 · DK · contact PI
Administrative Component$256,406
P30 · FY2011 · DK · contact PI
UAB CF Research and Translation Core Center$861,058
P30 · FY2010 · DK · contact PI
Tumor Sensitization to Purine Analogs by E. coli PNP$334,582
R01 · FY2010 · CA · contact PI
Administrative Component$256,406
P30 · FY2010 · DK · contact PI
UAB CF Research and Translation Core Center$861,058
P30 · FY2009 · DK · contact PI
Tumor Sensitization to Purine Analogs by E. coli PNP$335,274
R01 · FY2009 · CA · contact PI
Administrative Component$276,211
P30 · FY2009 · DK · contact PI
UAB CF Research and Translation Core Center$204,401
P30 · FY2009 · DK · contact PI
UAB CF Research and Translation Core Center$66,510
P30 · FY2009 · DK · contact PI
UAB CF Research and Translation Core Center$861,058
P30 · FY2008 · DK · contact PI
Tumor Sensitization to Purine Analogs by E. coli PNP$332,765
R01 · FY2008 · CA · contact PI
Administrative Component$234,816
P30 · FY2008 · DK · contact PI
UAB CF Research and Translation Core Center$726,834
P30 · FY2007 · DK · contact PI
Tumor Sensitization to Purine Analogs by E. coli PNP$309,985
R01 · FY2007 · CA · contact PI
Administrative Component$234,814
P30 · FY2007 · DK · contact PI
(SCOR) Mechanistic Studies of CF Pathogenesis and CL- S*$853,192
P50 · FY2006 · DK · contact PI
Tumor Sensitization to Purine Analogs by E. coli PNP$327,640
R01 · FY2006 · CA · contact PI
(SCOR) Mechanistic Studies of CF Pathogenesis and CL- S*$879,579
P50 · FY2005 · DK
(SCOR) Mechanistic Studies of CF Pathogenesis and CL- S*$879,579
P50 · FY2004 · DK
Frequent Isotonic Saline Therapy in Cystic Fibrosis$4,981
M01 · FY2004 · RR
(SCOR) Mechanistic Studies of CF Pathogenesis and CL- S*$879,579
P50 · FY2003 · DK
CYSTIC FIBROSIS GENE THERAPY CORE CENTER$717,501
P30 · FY2003 · DK
(SCOR) Mechanistic Studies of CF Pathogenesis and CL- S*$879,326
P50 · FY2002 · DK
CYSTIC FIBROSIS GENE THERAPY CORE CENTER$712,500
P30 · FY2002 · DK
CORE--VECTOR LABORATORY$197,422
P30 · FY2002 · HD
AMINOGLYCOSIDE ANTIBIOTICS FOR CYSTIC FIBROSIS$175,256
M01 · FY2002 · RR
CORE--CLINICAL ASSAY$165,355
P30 · FY2002 · DK
IN VIVO CANCER GENE THERAPY MODELS USING E COLI PNP$0
U19 · FY2002 · CA
CYSTIC FIBROSIS GENE THERAPY CORE CENTER$717,500
P30 · FY2001 · DK
(SCOR) MOLECULAR ASPECTS OF CFTR CELLULAR BIOLOGY$661,132
P50 · FY2001 · DK
CORE--VECTOR LABORATORY$197,422
P30 · FY2001 · HD
AMINOGLYCOSIDE ANTIBIOTICS FOR CYSTIC FIBROSIS$175,256
M01 · FY2001 · RR
CORE--CLINICAL ASSAY$165,355
P30 · FY2001 · DK
IN VIVO CANCER GENE THERAPY MODELS USING E COLI PNP$0
U19 · FY2001 · CA
BIOCHEMICAL STUDIES OF THE CYSTIC FIBROSIS GENE PRODUCT$0
P50 · FY2001 · DK
CYSTIC FIBROSIS GENE THERAPY CORE CENTER$717,500
P30 · FY2000 · DK
(SCOR) MOLECULAR ASPECTS OF CFTR CELLULAR BIOLOGY$661,132
P50 · FY2000 · DK
BIOCHEMICAL STUDIES OF THE CYSTIC FIBROSIS GENE PRODUCT$153,400
P50 · FY2000 · DK
CORE--CLINICAL ASSAY$64,605
P30 · FY2000 · DK
CORE--VECTOR LABORATORY$41,439
P30 · FY2000 · HD
AMINOGLYCOSIDE ANTIBIOTICS FOR CYSTIC FIBROSIS$29,529
M01 · FY2000 · RR
IN VIVO CANCER GENE THERAPY MODELS USING E COLI PNP$0
U19 · FY2000 · CA